Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
最新の財務諸表(Form-10K)によると、Check Cap Ltdの総資産は$0で、純損失は$0です。
MBAIの主要な財務比率は何ですか?
Check Cap Ltdの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Check Cap Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
Check Cap Ltd の最大収益セグメントは Banking and Related Activities で、最新の利益発表における収益は 44,992,000 です。地域別に見ると、United States が Check Cap Ltd の主要市場であり、収益は 44,992,000 です。